- Home
- BRLT vs JSPR Comparison
BRLT vs JSPR Comparison
Compare BRLT & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRLT | JSPR |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.5M | 26.3M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BRLT | JSPR |
|---|---|---|
| Price | $1.52 | $0.50 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $1.62 | N/A |
| AVG Volume (30 Days) | 58.8K | ★ 397.5K |
| Earning Date | 11-05-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.22 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $437,483,000.00 | N/A |
| Revenue This Year | $5.10 | N/A |
| Revenue Next Year | $5.13 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.63 | N/A |
| 52 Week Low | $1.00 | $0.32 |
| 52 Week High | $2.90 | $2.42 |
Technical Indicators
Market Signals| Indicator | BRLT | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 54.64 | 40.43 |
| Support Level | $1.26 | $0.45 |
| Resistance Level | $1.63 | $0.67 |
| Average True Range (ATR) | 0.08 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 63.64 | 36.05 |
Price Performance
Historical ComparisonAbout BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc is an digitally native omnichannel jewelry company selling The company's products include rings, necklaces, earrings, and bracelets. Its collection of premium-quality diamond engagement and wedding rings, gemstone rings, and fine jewelry is conceptualized by in-house design studio. The company operates in one operating and reporting segment, the retail sale of diamonds, gemstones and jewelry.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.